AZ and Novoheart aim to develop new heart failure drugs using Novoheart’s 3-D ventricular cardiac organoid chamber technology, which reproduces the characteristics of heart failure.
This strategic collaboration integrates Novoheart’s human Heart-in-a-Jar technology with Curi Bio’s Pulse analytics platform, delivering an solution for accelerated, high-content, human-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback